Overview
1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care
Accomplishments
1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care
Accomplishments
1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.
Current Appointments & Affiliations
George Barth Geller Distinguished Professor for Research in Cancer
·
2005 - Present
Medicine, Medical Oncology,
Medicine
Professor of Medicine
·
1997 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
1974 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Journal Article J Immunother Cancer · February 4, 2025 BACKGROUND: Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. METHODS: This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, cli ... Full text Link to item CiteComplement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.
Journal Article Nat Commun · January 2, 2025 GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b study dose escalation trial of GT103 in re ... Full text Open Access Link to item CitePonsegromab for the Treatment of Cancer Cachexia.
Journal Article N Engl J Med · December 19, 2024 BACKGROUND: Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b stud ... Full text Link to item CiteRecent Grants
NCI National Clinical Trials Network (UG1)
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2026A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
Clinical TrialPrincipal Investigator · Awarded by Clinipace, Inc. · 2016 - 2026Phase Ib Study of MEM-288 Oncolytic Virus in Combination with Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
ResearchCo-Mentor · Awarded by Bristol-Myers Squibb Foundation · 2023 - 2026View All Grants
Education, Training & Certifications
Ohio State University ·
1974
M.D.